AR signaling in Hormone Refractory Prostate Cancer
激素难治性前列腺癌中的 AR 信号传导
基本信息
- 批准号:6683441
- 负责人:
- 金额:$ 8.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-08-01 至 2005-07-31
- 项目状态:已结题
- 来源:
- 关键词:androgen receptor androgens athymic mouse gene expression gene mutation hormone regulation /control mechanism hormone related neoplasm /cancer hormone sensitivity /resistance hormone therapy human tissue immunocytochemistry male neoplasm /cancer chemotherapy neoplasm /cancer therapy neoplastic process nucleic acid sequence patient oriented research prognosis prostate neoplasms prostate specific antigen prostate surgery protooncogene transcription factor
项目摘要
DESCRIPTION (provided by applicant):
The androgen receptor (AR) mediates androgen signaling in the prostate and plays a vital role during all phases of prostate cancer development including the final androgen-independent phases. Somatic AR mutations, increased AR expression, increased AR coactivator expression and/or AR androgen-independent activity are all potential mechanisms causing prostate cancer progression to androgen-independent disease. Such aberrant AR activities might affect and/or predict time to hormone ablation therapy failure. Since clinical practice at present does not consider these mechanisms in choice or timing of treatment, we propose the use of aggressive chemotherapy and/or alternative androgen ablation treatments in conjunction with knowledge of the underlying mechanism of failure. We propose that response to chemo- or alternative hormone ablation therapy will be affected by the underlying AR mechanism of the original ablation therapy failure. In specific aim #1, we will measure AR mutations and expression levels of AR, p160 coactivators and HER2 in archival tissue from men in cohorts representing different stages of disease. In specific aim #2, we intend to do a preclinical trial using the CWR22 tumor model in mice to test early therapy and how it relates to the particular molecular abnormality biologically selected for during the course of androgen ablation treatment. Overall our work will provide a molecular framework of hormone resistant prostate cancer, important indices of prognosis, and the basis for several future clinical trials in alternative treatment strategies of androgen-independent prostate cancer.
描述(由申请人提供):
雄激素受体(AR)介导前列腺中的雄激素信号传导,并在前列腺癌发展的所有阶段(包括最终的雄激素非依赖性阶段)中发挥重要作用。体细胞AR突变、AR表达增加、AR辅激活因子表达增加和/或AR雄激素非依赖性活性都是导致前列腺癌进展为雄激素非依赖性疾病的潜在机制。这种异常的AR活性可能影响和/或预测激素消融治疗失败的时间。由于目前的临床实践并没有考虑这些机制的选择或治疗时机,我们建议使用积极的化疗和/或替代雄激素消融治疗结合失败的潜在机制的知识。我们认为,对化疗或替代性激素消融治疗的反应将受到原始消融治疗失败的潜在AR机制的影响。在具体目标#1中,我们将测量代表不同疾病阶段的队列中男性存档组织中的AR突变和AR、p160共激活因子和HER 2的表达水平。在具体目标#2中,我们打算在小鼠中使用CWR 22肿瘤模型进行临床前试验,以测试早期治疗以及它如何与雄激素消融治疗过程中生物学选择的特定分子异常相关。总的来说,我们的工作将提供激素抵抗性前列腺癌的分子框架,预后的重要指标,以及未来几项雄激素非依赖性前列腺癌替代治疗策略的临床试验的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jacek Pinski其他文献
Jacek Pinski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jacek Pinski', 18)}}的其他基金
Targeted Therapy to Receptors for LH-RH in Prostate Cancer
前列腺癌 LH-RH 受体的靶向治疗
- 批准号:
8318844 - 财政年份:2010
- 资助金额:
$ 8.1万 - 项目类别:
Targeted Therapy to Receptors for LH-RH in Prostate Cancer
前列腺癌 LH-RH 受体的靶向治疗
- 批准号:
8135341 - 财政年份:2010
- 资助金额:
$ 8.1万 - 项目类别:
Targeted Therapy to Receptors for LH-RH in Prostate Cancer
前列腺癌 LH-RH 受体的靶向治疗
- 批准号:
8547781 - 财政年份:2010
- 资助金额:
$ 8.1万 - 项目类别:
PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU
PHI-54 IV 芬维A胺治疗恶性实体瘤患者的 I 期研究
- 批准号:
7982120 - 财政年份:2008
- 资助金额:
$ 8.1万 - 项目类别:
PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU
PHI-54 IV 芬维A胺治疗恶性实体瘤患者的 I 期研究
- 批准号:
7716722 - 财政年份:2008
- 资助金额:
$ 8.1万 - 项目类别:
PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU
PHI-54 IV 芬维A胺治疗恶性实体瘤患者的 I 期研究
- 批准号:
7603946 - 财政年份:2006
- 资助金额:
$ 8.1万 - 项目类别:
AR signaling in Hormone Refractory Prostate Cancer
激素难治性前列腺癌中的 AR 信号传导
- 批准号:
6782582 - 财政年份:2003
- 资助金额:
$ 8.1万 - 项目类别:
相似海外基金
Abnormalities in androgens and ovarian markers in reproductive-age racially and ethnically diverse women in a prospective longitudinal cohort
前瞻性纵向队列中不同种族和民族的育龄女性雄激素和卵巢标志物的异常
- 批准号:
10930196 - 财政年份:2023
- 资助金额:
$ 8.1万 - 项目类别:
Nonalcoholic Fatty Liver Disease (NAFLD) in Polycystic Ovary Syndrome: The Role of Androgens on Liver Injury and NAFLD Progression
多囊卵巢综合征中的非酒精性脂肪肝 (NAFLD):雄激素在肝损伤和 NAFLD 进展中的作用
- 批准号:
10735807 - 财政年份:2023
- 资助金额:
$ 8.1万 - 项目类别:
Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens
阐明细胞识别和响应不同水平雄激素的机制
- 批准号:
10418461 - 财政年份:2022
- 资助金额:
$ 8.1万 - 项目类别:
Sexual Differentiation of the Brain and Behaviour: Central and Peripheral Targets of Androgens
大脑和行为的性别分化:雄激素的中枢和外周目标
- 批准号:
RGPIN-2019-04999 - 财政年份:2022
- 资助金额:
$ 8.1万 - 项目类别:
Discovery Grants Program - Individual
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
- 批准号:
10570208 - 财政年份:2022
- 资助金额:
$ 8.1万 - 项目类别:
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
- 批准号:
10688086 - 财政年份:2022
- 资助金额:
$ 8.1万 - 项目类别:
Influence of Androgens on Tissue-Specific Lipid Metabolites and Liver Injury in Young Women with NAFLD
雄激素对患有 NAFLD 的年轻女性组织特异性脂质代谢和肝损伤的影响
- 批准号:
10355174 - 财政年份:2022
- 资助金额:
$ 8.1万 - 项目类别:
Use of novel 11-oxygenated androgens to improve diagnostic accuracy and therapeutics in polycystic ovary syndrome
使用新型 11-含氧雄激素提高多囊卵巢综合征的诊断准确性和治疗效果
- 批准号:
10431620 - 财政年份:2022
- 资助金额:
$ 8.1万 - 项目类别:
Defining the impact of androgens on uterine immune cell function during endometrial tissue repair
确定子宫内膜组织修复过程中雄激素对子宫免疫细胞功能的影响
- 批准号:
2744296 - 财政年份:2022
- 资助金额:
$ 8.1万 - 项目类别:
Studentship
Paxillin and Androgens in the Regulation of Ovarian Follicle Development
桩蛋白和雄激素在卵巢卵泡发育调节中的作用
- 批准号:
10525097 - 财政年份:2022
- 资助金额:
$ 8.1万 - 项目类别: